A complete application in a minute
Tailored resume and cover letter, ready to send.
Zealand Pharma A/S is seeking a Lead EDC Specialist to drive the implementation of an Electronic Data Capture system and to shape how we build clinical studies. You will lead EDC study builds in line with protocols and data standards, while setting up SOPs and ensuring ongoing system updates and governance.
You will collaborate with IT, data managers, and external partners to deliver high-quality data management and sustainable processes from day one.
Does it excite you to lead the implementation of an Electronic Data Capture (EDC) system and shape how we build clinical studies and do you have experience with EDC study build, CRF design and edit checks? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
Your new position As Lead EDC Specialist, you will play a key role in implementing EDC at Zealand Pharma, from setting up processes and Standard Operating Procedures (SOPs) to preparing colleagues for the new way of working.
Once the system is live, you will lead EDC study build in line with study protocols and our data standards, and keep the system and processes up to date.
As this is a new area for Zealand Pharma, the position offers a high degree of ownership, with room to shape processes and standards from the start.
You are a proactive and structured professional who takes ownership and moves things forward. With a strong eye for detail and quality, you balance a hands‑on approach with a clear view of the bigger picture. You enjoy working across disciplines and are comfortable collaborating with colleagues in IT, clinical operations and external partners and you communicate clearly while balancing quality, compliance, and timelines.
The data management team consists of 8 clinical data managers and is part of Biometrics. The team oversees data management activities across studies, with most activities outsourced to CROs. As Lead EDC Specialist, you will be the team’s in‑house EDC expert, working closely with data managers, IT, and other functions involved in clinical studies. The team has an open and collaborative atmosphere where everyone is empowered to work independently and support each other when needed.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late‑stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at https://www.zealandpharma.com.
#LI-Onsite Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long‑standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high‑profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co‑development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.